Bone metastases in bladder cancer predict worse outcomes

CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.
However, median overall survival was better in patients with high PD-L1 expression treated with durvalumab monotherapy or durvalumab plus tremelimumab in patients with and without bone metastases.
“Bone metastases are associated with significant morbidity and mortality in metastatic urothelial carcinoma. Despite this, the independent impact of bone metastases

CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.
However, median overall survival was better in patients with high PD-L1 expression treated with durvalumab monotherapy or durvalumab plus tremelimumab in patients with and without bone metastases.
“Bone metastases are associated with significant morbidity and mortality in metastatic urothelial carcinoma. Despite this, the independent impact of bone metastases